share_log

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255

大摩资源lof维持在阿里拉姆制药的股票评级为中性,并将目标价上调至255美元。
Benzinga ·  07/12 13:16

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $250 to $255.

大摩资源lof分析师Michael Ulz保持阿里拉姆制药(纳斯达克:ALNY)的等权重评级,将目标价从$250上调至$255。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发